Fate Therapeutics (NASDAQ:FATE) reported quarterly earnings results on August 13, 2026 that exceeded analyst expectations.
At publication ·
Fate Therapeutics (NASDAQ:FATE) · earnings beat
At a glance
Fate Therapeutics (NASDAQ:FATE) reported quarterly earnings results on August 13, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.25, beating the consensus estimate of $-0.26 by $0.01 per share. Revenue came in at $2.1M, beating the estimate of $1.2M.
Fate Therapeutics's stock moved following the earnings release. The stock currently trades at $2.52 with a market capitalization of $128.0M.
Fate Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Fate Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
| Quarter | EPS Actual | EPS Est. | Surprise |
|---|---|---|---|
| Q2 (Aug 2026) | $-0.25 | $-0.26 | +3.8% |
| Q1 (May 2026) | $-0.26 | $-0.28 | +7.1% |
| Q4 (Feb 2026) | $-0.27 | $-0.27 | +0.0% |
Related Tools: Earnings Calendar | View FATE Stock Page
Check the latest earnings dates on our FATE earnings page or the Earnings Calendar.
See the full Q2 results including EPS actual vs estimate on our FATE earnings page.
Current market data
NASDAQ · FATE
$2.52
Down: -$0.20 · -7.35%
Live quote updated
Keep reading
